Clinical trial

EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

NCT04743453

Study summary

ClinicalTrials.gov

EFFECT OF ADDING DAPAGLIFLOZIN TO ALLOGRAFT DYSFUNCTION OF RENAL TRANSPLANTED PATIENTS.

Design: INTERVENTIONAL · Status: COMPLETED · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Dapagliflozin Normalized identity: dapagliflozin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Placebo Find medicine records · Find other trials using this name

StatusCOMPLETED

Study typeINTERVENTIONAL

Start date2021-08-17

PhasePHASE4

Conditions

Kidney Transplantationunresolved

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Diabetes Complicationsunresolved

Interventions

DapagliflozinDRUG · verified · RxNorm: dapagliflozin

PlaceboDRUG

Sponsors & collaborators

University of Sao Paulo General Hospitallead sponsor

Federal University of São Paulocollaborator

Mapped research locations

São PauloBrazil1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT04743453 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.